Seelos offering
Web10 Mar 2024 · NEW YORK, March 10, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous ... Web29 Mar 2024 · Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet …
Seelos offering
Did you know?
Web10 Mar 2024 · Seelos plans to use the net proceeds for general corporate purposes and to develop its product candidates. The offering is expected to close by March 14. SEEL -9.27% to $0.54 premarket March 10... Web20 May 2024 · Seelos intends to use an aggregate of $6.3 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes and the remainder for general ...
Web10 Mar 2024 · Seelos estimates gross proceeds from the offering will be approximately $11.24 million, before deducting fees payable to financial advisors and other estimated … Web10 Mar 2024 · Seelos Therapeutics Prices Direct Offering With Proceeds of $11.2M. Seelos Therapeutics Inc. said Friday it has entered into an agreement with a life sciences …
Web23 Aug 2024 · Seelos Therapeutics launches $6.7 million direct share offering with certain institutional investors The company intends to use the net proceeds for general corporate … Web19 May 2024 · NEW YORK, May 19, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL ), a clinical-stage biopharmaceutical company focused on the development of …
Web8 Mar 2024 · Seelos estimates gross proceeds from the offering will be approximately $11.24 million , before deducting fees payable to financial advisors and other estimated offering expenses payable by Seelos ...
Web24 May 2024 · Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares. Guggenheim … reg d withdrawalsWeb23 Aug 2024 · Seelos Therapeutics Inc ( Nasdaq:SEEL) announced Friday a $6.7 million registered direct share offering with certain institutional investors. The clinical-stage biopharmaceutical company is... regeal theater bussniess phone numberWeb20 May 2024 · Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous sy... Green Stock … regea coversWeb10 Mar 2024 · NEW YORK, March 10, 2024 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on... regeal sherwood stainless steelWeb13 Apr 2024 · Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and … probiotics lactobacillus reuteri powderWeb26 Jan 2024 · Seelos anticipates the aggregate net proceeds from the offering will be approximately $29.1 million, after deducting the underwriting discounts and commissions … rege antonymWeb13 Feb 2024 · Seelos intends to use the net proceeds from the offering for general corporate purposes and to advance the development of its product candidates. Raj … regea band